People

Stephen J. Kron, MD PhD

The Kron laboratory is a diverse and collaborative group of cell biologists, geneticists, biochemists, chemists and computer scientists. Our current basic research and technology efforts include 1) defining roles for chromatin dynamics and cell cycle regulation in DNA damage checkpoint response and cellular senescence, 2) dissecting cross-talk between metabolism and DNA damage response, 3) developing novel molecular assays to interrogate cell signaling in cancer, and 4) implementing novel mass spectrometry approaches to enable quantitative proteomics. We also pursue translational projects directed at 1) discovering inhibitors of cellular response to DNA double strand breaks as an approach to radiosensitization, 2) examining DNA damage and repair in tissues and tumors, and 3) exploiting DNA damage responses to induce anti-tumor immune responses.

Whitehead Institute
Cambridge MA
- Genetics
1995

Stanford University
Stanford CA
PhD - Cell Biology
1990

Stanford University
Stanford CA
MD - Medicine
1990

University of Pennsylvania
Philadelphia PA
MSE - Bioengineering
1983

University of Pennsylvania
Philadelphia PA
BA - Biochemistry
1982

Nuclear Sphingosine-1-phosphate Lyase Generated ?2-hexadecenal is A Regulator of HDAC Activity and Chromatin Remodeling in Lung Epithelial Cells.
Ebenezer DL, Ramchandran R, Fu P, Mangio LA, Suryadevara V, Ha AW, Berdyshev E, Van Veldhoven PP, Kron SJ, Schumacher F, Kleuser B, Natarajan V. Nuclear Sphingosine-1-phosphate Lyase Generated ?2-hexadecenal is A Regulator of HDAC Activity and Chromatin Remodeling in Lung Epithelial Cells. Cell Biochem Biophys. 2021 Jun 03.
PMID: 34085165

Loss of a 7q gene, CUX1, disrupts epigenetic-driven DNA repair and drives therapy-related myeloid neoplasms.
Imgruet MK, Lutze J, An NN, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher DJ, Gurbuxani S, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetic-driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 May 26.
PMID: 34041524

Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy.
Prasanna PG, Citrin DE, Hildesheim J, Ahmed MM, Venkatachalam S, Riscuta G, Xi D, Zheng G, van Deursen J, Goronzy J, Kron SJ, Anscher MS, Sharpless NE, Campisi J, Brown SL, Niedernhofer LJ, O'Loghlen A, Georgakilas AG, Paris F, Gius D, Gewirtz DA, Schmitt CA, Abazeed ME, Kirkland JL, Richmond A, Romesser PB, Lowe SW, Gil J, Mendonca MS, Burma S, Zhou D, Coleman CN. Therapy-Induced Senescence: Opportunities to Improve Anti-Cancer Therapy. J Natl Cancer Inst. 2021 Apr 01.
PMID: 33792717

Subcellular localization of the J-protein Sis1 regulates the heat shock response.
Feder ZA, Ali A, Singh A, Krakowiak J, Zheng X, Bindokas VP, Wolfgeher D, Kron SJ, Pincus D. Subcellular localization of the J-protein Sis1 regulates the heat shock response. J Cell Biol. 2021 01 04; 220(1).
PMID: 33326013

Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons.
Flor A, Wolfgeher D, Li J, Hanakahi LA, Kron SJ. Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons. Cell Chem Biol. 2021 Jun 17; 28(6):776-787.e8.
PMID: 33352117

Small-molecule drug repurposing to target DNA damage repair and response pathways.
Brinkman JA, Liu Y, Kron SJ. Small-molecule drug repurposing to target DNA damage repair and response pathways. Semin Cancer Biol. 2021 Jan; 68:230-241.
PMID: 32113999

Targeted Covalent Inhibition of Telomerase.
Betori RC, Liu Y, Mishra RK, Cohen SB, Kron SJ, Scheidt KA. Targeted Covalent Inhibition of Telomerase. ACS Chem Biol. 2020 03 20; 15(3):706-717.
PMID: 32017522

The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair.
Moreno NS, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA. The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. Nucleic Acids Res. 2019 11 04; 47(19):10475.
PMID: 31511892

Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer.
Ricco N, Flor A, Wolfgeher D, Efimova EV, Ramamurthy A, Appelbe OK, Brinkman J, Truman AW, Spiotto MT, Kron SJ. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. Mol Oncol. 2019 09; 13(9):1927-1943.
PMID: 31225926

Immune profiles in primary squamous cell carcinoma of the head and neck.
Saloura V, Izumchenko E, Zuo Z, Bao R, Korzinkin M, Ozerov I, Zhavoronkov A, Sidransky D, Bedi A, Hoque MO, Koeppen H, Keck MK, Khattri A, London N, Kotlov N, Fatima A, Vougiouklakis T, Nakamura Y, Lingen M, Agrawal N, Savage PA, Kron S, Kline J, Kowanetz M, Seiwert TY. Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncol. 2019 09; 96:77-88.
PMID: 31422218

View All Publications